Gene therapy of cancer (Registro nro. 207145)

MARC details
000 -LÍDER
fixed length control field 05063cam a2200649Ki 4500
001 - NÚMERO DE CONTROL
control field u380224
003 - IDENTIFICADOR DEL NÚMERO DE CONTROL
control field SIRSI
005 - FECHA Y HORA DE LA ULTIMA TRANSACCIÓN
control field 20160812084637.0
006 - ELEMENTOS DE LONGITUD FIJA - CARACTERÍSTICAS DE MATERIALES ADICIONALES - INFORMACIÓN GENERAL
fixed length control field m o d
007 - CAMPO FIJO DE DESCRIPCIÓN FIJA--INFORMACIÓN GENERAL
fixed length control field cr cnu---unuuu
008 - ELEMENTOS DE LONGITUD FIJA -- INFORMACIÓN GENERAL
fixed length control field 130909s2014 ne a ob 001 0 eng d
040 ## - FUENTE DE CATALOGACIÓN
Original cataloging agency NT
Language of cataloging eng
Description conventions rda
-- pn
Transcribing agency NT
Modifying agency UIU
-- OPELS
-- YDXCP
-- BUF
-- OPELS
-- OCLCF
-- UIU
-- OCLCQ
-- OCLCO
-- VAM
-- VZR
019 ## -
-- 861477955
020 ## - NÚMERO INTERNACIONAL NORMALIZADO PARA LIBROS
International Standard Book Number 9780123946324
Qualifying information (electronic bk.)
020 ## - NÚMERO INTERNACIONAL NORMALIZADO PARA LIBROS
International Standard Book Number 0123946328
Qualifying information (electronic bk.)
020 ## - NÚMERO INTERNACIONAL NORMALIZADO PARA LIBROS
Canceled/invalid ISBN 9780123942951
020 ## - NÚMERO INTERNACIONAL NORMALIZADO PARA LIBROS
Canceled/invalid ISBN 0123942950
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier DEBSZ
System control number 405350600
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier NLGGC
System control number 369326989
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier NZ1
System control number 15195162
050 #4 - SIGNATURA TOPOGRÁFICA DE LA BIBLIOTECA DEL CONGRESO
Classification number RC271.G45
Item number G485 2014
082 04 - NÚMERO DE CLASIFICACIÓN DECIMAL DEWEY
Classification number 616.994042
Edition number 23
049 ## - LOCAL HOLDINGS (OCLC)
Holding library TEFA
245 00 - MENCIÓN DE TITULO
Title Gene therapy of cancer
Medium [recurso electrónico] :
Remainder of title translational approaches from preclinical studies to clinical implementation /
Statement of responsibility, etc. edited by Edmund Lattime, Stanton Gerson.
250 ## - MENCIÓN DE EDICIÓN
Edition statement Third edition.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Amsterdam :
Name of producer, publisher, distributor, manufacturer Academic Press,
Date of production, publication, distribution, manufacture, or copyright notice 2014.
300 ## - DESCRIPCIÓN FÍSICA
Extent 1 online resource.
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
504 ## - NOTA DE BIBLIOGRAFÍA, ETC.
Bibliography, etc Includes bibliographical references and index.
505 0# - NOTA DE CONTENIDO
Formatted contents note Ex Vivo Gene Therapy: Utilization of Genetic Vectors for the Generation of Genetically Modified Cell Products for Therapy -- Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factor-a -- Viral Insertion Site Detection and Analysis in Cancer Gene Therapy -- Targeted Systemic Delivery of Therapeutic siRNA -- Bacterial Delivery of RNAi Effectors -- Gene-Directed Enzyme Prodrug Cancer Therapy -- Electroporation Gene Therapy -- Toxin-Based Cancer Gene Therapy: Under the Control of Oncofetal H19 Regulatory Sequences -- Gene Therapy in Radiotherapy of Cancer -- Advances in Oncolytic Virotherapy for Brain Tumors -- Oncolytic Adenoviruses in the Treatment of Cancer in Humans -- Selectively Replicating Oncolytic Adenoviruses Combined with Chemotherapy, Radiotherapy, or Molecular Targeted Therapy for Treatment of Human Cancers -- Reoviral Therapy for Cancer: Strategies for Improving Antitumor Efficacy Using Radio- and Chemotherapy -- Selectively Replicating Herpes Simplex Viral Vectors -- Modified Oncolytic Herpesviruses for Gene Therapy of Cancer -- The Lister Strain of Vaccinia Virus as an Anticancer Therapeutic Agent -- Poxvirus-Based Strategies for Combined Vaccine and Tumor Microenvironment Manipulation -- Genetically Engineered (T Cell Receptor) T Cells for AdoptiveTherapy -- Genetically Modified Dendritic Cell Vaccines for Solid Tumors -- Dendritic Cell Vaccination -- Chemokine Gene-Modified Dendritic Cells for Cancer Therapy -- The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors -- Clinical Application of Plasmid-Based Cancer Vaccines -- Lentivector Vaccines -- Therapeutic Efficacy and Systemic Antitumor T Cell Immunity Induced by RheoSwitch-Regulated IL-12 Expression after Intratumoral Injection of Adenovirus Vector or Vector-Transduced Dendritic Cells -- Clinical Trials Using LV-P₁₄₀K-MGMT for Gliomas -- RNA Interference Therapeutics for Tumor Therapy: Promising Work in Progress -- MGMT Stem Cell Selection and Protection: Preclinical Large Animal and Clinical Studies -- Cytidine Deaminase in Myeloprotective Gene Therapy -- Genetically Engineered Salmonella typhimurium for Targeted Cancer Therapy -- Imaging of Oncolytic Virus Gene Expression -- Lentiviral-Encoded Sodium Iodide Symporter-Mediated Cancer Gene Therapy -- Bacteriophage: From Bacteria to a Successful Targeted Systemic Gene Delivery for Cancer -- Issues in Moving Gene Therapy Approaches to Early Clinical Trials -- The FDA Review Process for Cancer Gene Therapy -- Ethics in Translational Gene Transfer Research.
588 0# - SOURCE OF DESCRIPTION NOTE
Source of description note Print version record.
596 ## -
-- 19
650 #0 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element Cancer
General subdivision Gene therapy
Form subdivision Laboratory manuals.
650 #0 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element Cancer
General subdivision Immunotherapy.
650 12 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element Neoplasms
General subdivision genetics.
650 12 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element Neoplasms
General subdivision therapy.
650 22 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element Genetic Therapy
General subdivision methods.
650 22 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element Immunotherapy
General subdivision methods.
650 22 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element Protein Biosynthesis.
650 #7 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element HEALTH & FITNESS
General subdivision Diseases
-- General.
Source of heading or term bisacsh
650 #7 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element MEDICAL
General subdivision Clinical Medicine.
Source of heading or term bisacsh
650 #7 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element MEDICAL
General subdivision Diseases.
Source of heading or term bisacsh
650 #7 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element MEDICAL
General subdivision Evidence-Based Medicine.
Source of heading or term bisacsh
650 #7 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element MEDICAL
General subdivision Internal Medicine.
Source of heading or term bisacsh
650 #7 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element Cancer
General subdivision Gene therapy.
Source of heading or term fast
Authority record control number (OCoLC)fst00845367
650 #7 - ASIENTO SECUNDARIO DE MATERIA - TERMINO TEMÁTICO
Topical term or geographic name as entry element Cancer
General subdivision Immunotherapy.
Source of heading or term fast
Authority record control number (OCoLC)fst00845386
655 #4 -
-- Electronic books.
655 #7 -
-- Handbooks, manuals, etc.
-- fast
-- (OCoLC)fst01423877
700 1# - ASIENTO SECUNDARIO - NOMBRE PERSONAL
Personal name Lattime, Edmund C.,
Dates associated with a name 1951-
Relator term editor.
700 1# - ASIENTO SECUNDARIO - NOMBRE PERSONAL
Personal name Gerson, Stanton L.,
Relator term editor.
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Print version:
Title Gene therapy of cancer.
Edition Third edition
International Standard Book Number 9780123942951
Record control number (OCoLC)839312810
856 40 - LOCALIZACIÓN Y ACCESO ELECTRÓNICOS
Public note Libro electrónico
Materials specified ScienceDirect
Uniform Resource Identifier <a href="http://148.231.10.114:2048/login?url=http://www.sciencedirect.com/science/book/9780123942951">http://148.231.10.114:2048/login?url=http://www.sciencedirect.com/science/book/9780123942951</a>
942 ## - TIPO DE MATERIAL (KOHA)
Koha item type Libro Electrónico
Existencias
Estado de retiro Fuente de clasificación Colección Ubicación permanente Ubicación actual Fecha de ingreso Total Checkouts Signatura topográfica Código de barras Date last seen Número de copia Tipo de material
    Colección de Libros Electrónicos Biblioteca Electrónica Biblioteca Electrónica     RC271 .G45 G485 2014 380224-2001 12/08/2016 1 Libro Electrónico

Con tecnología Koha